PremiumThe FlyPerspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01 Bristol Myers announces EC approval of Breyanzi 2seventy Bio price target lowered to $5 from $6 at Morgan Stanley PremiumThe Fly2seventy Bio downgraded to Market Perform from Outperform at Leerink 2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash PremiumThe FlyBristol Myers CEO bought $110K in common stock FDA accepts Bristol Myers’ sBLA for Opdivo plus Yervoy Bristol-Myers Squibb: Balancing Growth and Challenges Amidst Market Dynamics – A Hold Recommendation 
